Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Published . Updated .
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Directly affected
- LLY Eli Lilly
Named in this report.
Indirectly affected
- XOP STATE STREET SPDR S&P OIL & GAS EXPLORATION & PRODUCTION ETF
GA selected XOP as a RELATED security because its canonical security name directly matches this event's themes: production. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Source: CNBC Top
Eli Lilly (LLY) since this story, compared with the market
Since the first closing price after “Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production,” Eli Lilly (LLY) is +6.00%. The S&P 500 fund (SPY) is -0.88% over the same days, a +6.88% difference versus the market.
Disclosure records for Eli Lilly (LLY) within two months of 21 Sep 2026
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 17 days before publication, inside 30 days. The filing is listed beside the story “Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production.”
- Donald J Trump buy Eli Lilly (LLY) ($15,001 - $50,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Eli Lilly (LLY)
Companies tied to this story
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, high confidence in the 21 Sep 2026 story “Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production.” Reason on file: The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
- XOP State Street Spdr S&P Oil & Gas Exploration & Production Etf
State Street Spdr S&P Oil & Gas Exploration & Production Etf (XOP) is linked, with no stored direction, medium confidence in the 21 Sep 2026 story “Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production.” Reason on file: GA selected XOP as a RELATED security because its canonical security name directly matches this event's themes: production. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Eli Lilly (LLY)
“Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production” (21 Sep 2026) reaches Eli Lilly (LLY) through this story.
For Eli Lilly (LLY), the reason on file says The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
State Street Spdr S&P Oil & Gas Exploration & Production Etf (XOP) is here too. Its reason reads: GA selected XOP as a RELATED security because its canonical security name directly matches this event's themes: production. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Eli Lilly (LLY) price range
LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65. XOP traded between 177.09 and 202.25 across 20 sessions. The latest close on file is 199.52.
What the saved facts support for Eli Lilly (LLY)
21 out of 100
“Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.